Key facts
- Notable investors include Industrifonden, Nordic Mentor Network For Entrepreneurship, DRIVE ( KI Innovations Business Incubator), Stockholm University.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for ToxoTech
- ·The full record, as it builds
Funding rounds
No funding rounds for ToxoTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ToxoTech
Developer of toxin-based biological products intended for neuromuscular and neurological disorders. The company uses protein engineering and structural biology to create recombinant, precision-engineered toxins with optimized receptor interactions, enabling healthcare organizations to improve patient outcomes.
- Sector
- Healthcare
- HQ
- Jarfalla, Sweden
- Founded
- 2020
- Employees
- 4
- Website
- toxotech.se/
- Ownership
- Privately Held (backing)
ToxoTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ToxoTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ToxoTech in its N-PORT filings yet. We sweep new filings monthly.